The estimated Net Worth of Edward J Iii Dulac is at least 3.27 百万$ dollars as of 4 March 2024. Mr. Dulac owns over 2,447 units of Fate Therapeutics Inc stock worth over 393,739$ and over the last 4 years he sold FATE stock worth over 2,881,038$. In addition, he makes 0$ as Chief Financial Officer at Fate Therapeutics Inc.
Edward has made over 13 trades of the Fate Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,447 units of FATE stock worth 19,013$ on 4 March 2024.
The largest trade he's ever made was selling 19,460 units of Fate Therapeutics Inc stock on 28 September 2021 worth over 1,216,834$. On average, Edward trades about 4,057 units every 46 days since 2020. As of 4 March 2024 he still owns at least 101,479 units of Fate Therapeutics Inc stock.
You can see the complete history of Mr. Dulac stock trades at the bottom of the page.
Edward J. Dulac III serves as Chief Financial Officer of the Company. Prior to joining the Company, Mr. Dulac, age 45, was Vice President of Business Development & Strategy from 2017 to 2020, and held roles of increasing responsibility in business development, portfolio development strategy and commercial planning since 2012, at Celgene Corporation, a biotechnology company acquired by Bristol-Myers Squibb in 2019. From 2007 to 2012, Mr. Dulac was a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers, prior to which he worked in corporate finance at Pfizer Inc. Mr. Dulac received a B.S. in Pharmacy from the University of Pittsburgh and an M.B.A. from the Kelley School of Business at Indiana University.
Edward Dulac is 45, he's been the Chief Financial Officer of Fate Therapeutics Inc since 2020. There are 12 older and 3 younger executives at Fate Therapeutics Inc. The oldest executive at Fate Therapeutics Inc is William Rastetter, 72, who is the Independent Chairman of the Board.
Edward's mailing address filed with the SEC is C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE, MA, 02139.
Over the last 11 years, insiders at Fate Therapeutics Inc have traded over 48,476,146$ worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth 162,421,037$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Associates V Lpvenrock Part...、Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of 384,496$. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth 2,678$.
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
Fate Therapeutics Inc executives and other stock owners filed with the SEC include: